Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Edgewise Therapeutics (EWTX) Operating Income (2020 - 2026)

Edgewise Therapeutics has reported Operating Income over the past 7 years, most recently at -$54.1 million for Q1 2026.

  • Quarterly results put Operating Income at -$54.1 million for Q1 2026, down 17.75% from a year ago — trailing twelve months through Mar 2026 was -$199.6 million (down 17.36% YoY), and the annual figure for FY2025 was -$191.4 million, down 20.51%.
  • Operating Income reached -$54.1 million in Q1 2026 per EWTX's latest filing, up from -$56.0 million in the prior quarter.
  • Across five years, Operating Income topped out at -$14.8 million in Q1 2022 and bottomed at -$56.0 million in Q4 2025.
  • Median Operating Income over the past 5 years was -$34.8 million (2024), compared with a mean of -$34.7 million.
  • The largest annual shift saw Operating Income plummeted 116.22% in 2022 before it fell 11.82% in 2025.
  • Over 5 years, Operating Income stood at -$22.1 million in 2022, then plummeted by 53.37% to -$33.9 million in 2023, then tumbled by 34.49% to -$45.5 million in 2024, then dropped by 22.92% to -$56.0 million in 2025, then rose by 3.33% to -$54.1 million in 2026.
  • Business Quant data shows Operating Income for EWTX at -$54.1 million in Q1 2026, -$56.0 million in Q4 2025, and -$46.9 million in Q3 2025.